
Amplimune® (100ml)
Amplimune, mycobacterium cell wall fraction (MCWF) immunostimulant, is CFIA-approved for the reduction of clinical signs and mortality associated with K99 E. coli diarrhea in neonatal calves.
Amplimune, mycobacterium cell wall fraction (MCWF) immunostimulant, is CFIA-approved for the reduction of clinical signs and mortality associated with K99 E. coli diarrhea in neonatal calves.
Amplimune, mycobacterium cell wall fraction (MCWF) immunostimulant, is CFIA-approved for the reduction of clinical signs and mortality associated with K99 E. coli diarrhea in neonatal calves.
Amplimune, mycobacterium cell wall fraction (MCWF) immunostimulant, is CFIA-approved for the reduction of clinical signs and mortality associated with K99 E. coli diarrhea in neonatal calves.
Immunocidin, mycobacterium cell wall fraction (MCWF) immunostimulant, is CFIA-approved for the intratumoral treatment of mixed mammary tumor and mammary adenocarcinoma in dogs.
Immunocidin Equine, mycobacterium cell wall fraction (MCWF) immunostimulant, is CFIA-approved for the intratumoral treatment of sarcoid tumors in horses.
Settle, mycobacterium cell wall fraction (MCWF) immunostimulant, is approved by the CFIA as an aid in the treatment of equine endometritis caused by Streptococcus zooepidemicus.